Akèy › Sendwòm myelodisplastik › Washington
Etid klinik pou Sendwòm myelodisplastik nan Washington
21 etid pou Sendwòm myelodisplastik ap chèche patisipan nan sit nan Washington.
Vil nan Washington
Tèks ofisyèl etid la (Anglè)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06577441A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1
Laj 12 a 78 · Tout sèks · Mizajou Sep 29, 2026 · NCT03802695MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Fred Hutchinson Cancer Center, Seattle
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- University of Washington, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT05320198CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04375631Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04282187Collection of Tissue Samples for Cancer Research
- Fred Hutchinson, Seattle
Ap rekriteEtid obsèvasyon
2 Months · Tout sèks · Mizajou Sep 16, 2026 · NCT00900198The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- ak 1 plis
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06529731Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2
6 Months – 65 Years · Tout sèks · Mizajou Jul 22, 2026 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 20, 2026 · NCT07046078Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2Volontè an sante akeyi
6 Months · Tout sèks · Mizajou May 29, 2026 · NCT04195633HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1
Jiska laj 80 · Tout sèks · Mizajou May 18, 2026 · NCT03326921Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2026 · NCT06928662A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Seattle Cancer Care Alliance, Seattle
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT05732103Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2
Laj 1 a 60 · Tout sèks · Mizajou Mar 12, 2026 · NCT03970096HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Fred Hutchinson Cancer Research Center, Seattle
Ap rekriteFaz 2
3 Months · Tout sèks · Mizajou Nov 12, 2025 · NCT02143830SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT06501196Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2025 · NCT06462365Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.